Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026)
Jade Biosciences posted quarterly Income from Continuing Operations of 40368000.0 for Q1 2026, down 5.76% year-on-year from 42835868.56 in Q1 2025, and down 26.57% on a QoQ basis from 31894000.0 in Q4 2025.
Jade Biosciences (JBIO) has 7 years of Income from Continuing Operations data on file, last reported at 40368000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 5.76% year-over-year to 40368000.0; the trailing twelve-month figure through Mar 2026 stood at 123359000.0 (down 22.96% YoY), and the FY2025 full-year result was 178000.0, up 100.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 40368000.0, down from 31894000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 45221000.0 in Q4 2023 and bottomed at 46979000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 19025000.0 (2023), against an average of 15632882.35.
- The widest annual swing landed in 2022, when Income from Continuing Operations jumped 434.4%; it then slumped 4254.03% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 27488000.0 in 2022, then jumped by 64.51% to 45221000.0 in 2023, then slumped by 203.89% to 46979000.0 in 2024, then jumped by 32.11% to 31894000.0 in 2025, then decreased by 26.57% to 40368000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40368000.0 (Q1 2026), 31894000.0 (Q4 2025), and 25147000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | -40.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | -31.89 Mn |
| Sep 30, 2025 | -25.15 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -46.98 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Jun 30, 2024 | -596,000.00 |
| Mar 31, 2024 | -23.19 Mn |
| Dec 31, 2023 | 45.22 Mn |
| Sep 30, 2023 | -19.56 Mn |
| Jun 30, 2023 | -19.03 Mn |
| Mar 31, 2023 | -16.52 Mn |
| Dec 31, 2022 | 27.49 Mn |
| Sep 30, 2022 | -13.59 Mn |
| Jun 30, 2022 | -11.99 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.22 Mn |
| Sep 30, 2021 | -6.18 Mn |
| Jun 30, 2021 | -5.78 Mn |
| Mar 31, 2021 | -2.78 Mn |
| Dec 31, 2020 | -3.66 Mn |
| Sep 30, 2020 | -2.24 Mn |
| Jun 30, 2020 | -1.66 Mn |